Discontinue semaglutide in patients who develop suicidal thoughts or behaviors
It wasn't like, "Oh." It was because I was no longer valuable taking 5 to 7 minutes with each person and seeing 40 patients a day
Some of these issues could be alleviated with robust human-based research, followed by FDA approval if warranted
[DOI] [PubMed] [Google Scholar] 17.Tissot N., Genty G., Santoprete R., Baltenneck F., Thibaut S., Michelet J.-F., Sequeira I., Bornschlgl T
Although stomach or gastrointestinal side effects are common, theyre usually mild
CJC-1295 Ipamorelin FDA status in 2026: approval, compounding, Category 2 safety concerns, and research-only availability